Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin

Annals of Hematology

Volumn 92, Issue 4, 2013, Pages 567-568

  Desai, Amrita ^a,c   Telang, Gladys H ^b,c   Olszewski, Adam J ^a,c  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CARMUSTINE; CD30 ANTIGEN; METHOTREXATE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10 VCMMAE; CAC10-VCMMAE;

AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; CONVALESCENCE; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ELECTRON THERAPY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LETTER; MALE; NEUROPATHY; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RECURRENT CANCER; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR BIOPSY; DRUG ADMINISTRATION; METHODOLOGY; REMISSION; SKIN TUMOR; TIME;

AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL; MALE; REMISSION INDUCTION; SKIN NEOPLASMS; TIME FACTORS;

EID: 84877032826     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1610-3     Document Type: Letter

References (10)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785. doi: 10.1182/blood-2004-09-3502
2. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R (2011) EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118:4024-4035. doi: 10.1182/blood-2011-05-351346
3. Fujita H, Nagatani T, Miyazawa M, Wada H, Koiwa K, Komatsu H, Ikezawa Z (2008) Primary cutaneous anaplastic large cell lymphoma successfully treated with low-dose oral methotrexate. Eur J Dermatol 18:360-361. doi: 10.1684/ejd.2008.0420
4. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH (2003) CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49:1049-1058. doi: 10.1016/S0190
5. Brice P, Cazals D, Mounier N, Verola O, Neidhart-Berard AM, Remenieras L, Deconinck E, Doyen C, Hamelsand J, Molina T, Moulonguet I, Gisselbrecht C (1998) Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Leukemia 12:213-219
6. Katz J, Janik JE, Younes A (2011) Brentuximab vedotin (SGN-35). Clin Cancer Res 17:6428-6436. doi: 10.1158/1078-0432.CCR-11-0488
7. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A (2012) Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. J Clin Oncol 30:2190-2196. doi: 10.1200/JCO.2011.38.0402
8. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189. doi: 10.1200/JCO.2011.38.0410
9. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821. doi: 10.1056/NEJMoa1002965
10. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH (2009) A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15:6217-6224. doi: 10.1158/1078-0432.CCR-09-0162